A5029048001- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- 3D Printing in Biomedical Research
- Bladder and Urothelial Cancer Treatments
- Tissue Engineering and Regenerative Medicine
- Estrogen and related hormone effects
- Fibroblast Growth Factor Research
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Melanoma and MAPK Pathways
- Immune Cell Function and Interaction
- Computational Drug Discovery Methods
- Neuroendocrine Tumor Research Advances
Hospital Del Mar
2016-2025
Centre for Biomedical Network Research on Rare Diseases
2019-2025
Centro de Investigación Biomédica en Red de Cáncer
2010-2025
Hospital del Mar Research Institute
2016-2025
Municipal Institute for Medical Research
2015-2025
Instituto de Salud Carlos III
2012-2025
Universitat Pompeu Fabra
2015-2024
GEICAM – Spanish Breast Cancer Group
2016-2024
Universitat Autònoma de Barcelona
1998-2023
Delfos Hospital
2019-2020
To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to explore its pharmacokinetic pharmacodynamic effects in patients with selected solid tumor types.This was phase I dose-escalating trial oral 150 mg/d maximum 1,000 given once daily for at least 28 days. Patients either advanced non-small-cell lung, ovarian, head neck, prostate, or colorectal cancer were recruited.Eighty-eight received (150 mg/d). At...
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of somatic variants remains an important bottleneck. Here we present Cancer Genome Interpreter, a versatile platform that automates newly sequenced cancer genomes, annotating potential alterations detected tumors to act as drivers their possible effect on treatment response. The results are organized different levels evidence according current knowledge, which envision can support...
To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer.In this phase II multicenter trial, primary objective was assessment tumor response rate gefitinib; secondary objectives included analysis pharmacodynamic biologic profiles healthy tissue.while phosphorylation mitogen-activated protein kinase inhibited both tissues, treatment induced p27 a decrease Ki67 skin but not tumors....
BackgroundRAS assessment is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination based on tumor tissue, however, genotyping of circulating (ct)DNA offers clear advantages as a minimally invasive method that represents heterogeneity. Our study aims to evaluate the use ctDNA an alternative determining baseline RAS status and subsequent monitoring mutations during component routine clinical practice.Patients methodsRAS mutational plasma was...
The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) 50% patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was result the or alone, we recruited third cohort who received without trastuzumab. We then investigated impact reintroducing to on monotherapy.Twenty-nine HER2-positive therapy (840 mg...
Abstract Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines treatment, molecular landscape resistant tumors must be ascertained. We investigated role mutations in EGFR signaling axis on acquisition patients and cellular models. Experimental Design: Tissue samples were obtained from 37 became refractory cetuximab. Colorectal cells sensitive treated until derivatives...
Abstract Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary tissues from patients. Intrinsic subtype was identified using a PAM50 classifier χ2 tests determined the differences variable distribution. The rate conversion 0% basal-like tumors, 23.1% HER2-enriched (HER2-E) 30.0% luminal B 55.3% A tumors. 40.2% cases, tumors converted...
Blockade of the epidermal growth factor receptor (EGFR) with monoclonal antibodies cetuximab or panitumumab is effective in a subset colorectal cancers (CRCs), but emergence resistance limits efficacy these therapeutic agents. At relapse, majority patients develop RAS mutations, while acquires EGFR extracellular domain (ECD) mutations. Here we find that who experience greater and longer responses to blockade preferentially ECD mutations emerge more frequently smaller tumour shrinkage shorter...
Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study explore the clinical relevance Lehmann TNBC by identifying any differences in response neoadjuvant among them. We determined gene expression profiling paraffined pre-treatment tumor biopsies from 125 patients treated anthracyclines and/or taxanes +/- carboplatin. explored clinicopathological characteristics...
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor metastasis pairs: 252 targeted gene sequencing, 152 RNA 67 single nucleotide polymorphism arrays), we found a driver role for GATA1 MEN1 somatic mutations. Metastases were enriched ESR1, PTEN, CDH1, PIK3CA, RB1 mutations; MDM4 MYC amplifications; ARID1A deletions. An increase clonality was...
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function proliferation, limiting the efficacy of adoptive NK therapies. Inspired by partial resistance to TGFβ cells with SMAD4 haploinsufficiency, we used CRISPR–Cas9 for knockout in human cells. Here show that SMAD4KO were resistant inhibition, retaining their cytotoxicity, cytokine secretion interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration control, both as...
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom) is under development as an anticancer agent. We studied the pharmacodynamic effects of on EGFR in skin, EGFR-dependent tissue, cancer patients participating phase I clinical trials.We 104 pre- and/or on-ZD1839 therapy ( approximately at day 28 therapy) skin biopsies from 65 receiving escalating doses daily oral ZD1839. measured activation by...